Lilly Presents Patient-Reported Outcomes from the Positive Phase 3 monarchE Trial for Verzenio® at St. Gallen Virtual Congress 2021 | BioSpace
PRO data further support the monarchE results to date for Verzenio for the treatment of HR+, HER2- high risk early breast cancer First disclosure of patient-reported outcomes for a Phase 3 study of a CDK4 & 6 inhibitor in the adjuvant setting for HR+, HER2- early breast cancer INDIANAPOLIS, March 17, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced patient-reported outcomes (PRO) for the investigational use of Verzenio (abemaciclib) in combination with standard adjuvant endocrine therapy (ET) for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) high risk early breast cancer (EBC).